Oxford Index Search Results


Refine by subject

 

Refine by type

Refine by product

 

Mackenzie

Overview page.

River in nw Canada. The longest river in Canada, it flows c.1,800km (1,120mi) nw from the Great Slave Lake to the Arctic Ocean. Between the Great Slave and Athabasca lakes ...

See overview in Oxford Index

Celecoxib increases <i>SMN</i> and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation

Faraz Farooq, Francisco Abadía-Molina, Duncan MacKenzie, Jeremiah Hadwen, Fahad Shamim, Sean O'Reilly, Martin Holcik and Alex MacKenzie.

in Human Molecular Genetics

September 2013; p ublished online May 2013 .

Journal Article. Subjects: Genetics and Genomics. 5642 words.

The loss of functional Survival Motor Neuron (SMN) protein due to mutations or deletion in the SMN1 gene causes autosomal recessive neurodegenerative spinal muscle atrophy (SMA). A...

Go to Oxford Journals »  abstract

P-03ETHANOL AFFECTS LIMBIC AND STRIATAL EXPRESSION OF VESICULAR GLUTAMATE TRANSPORTERS IN OUTBRED RATS EXPOSED TO EARLY LIFE STRESS

M. Vrettou, L. Granholm, A. Todkar, K. W. Nilsson, Å. Wallén-Mackenzie, I. Nylander and E. Comasco.

in Alcohol and Alcoholism

September 2015; p ublished online August 2015 .

Journal Article. Subjects: Public Health and Epidemiology. 248 words.

Go to Oxford Journals »  home page

Variation Over Time of the Effects of Prognostic Factors in a Population-based Study of Colon Cancer: Comparison of Statistical Models

Catherine Quantin, Michal Abrahamowicz, Thierry Moreau, Gillian Bartlett, Todd MacKenzie, Mohammed Adnane Tazi, Luc Lalonde and Jean Faivre.

in American Journal of Epidemiology

December 1999; p ublished online December 1999 .

Journal Article. Subjects: Public Health and Epidemiology. 0 words.

The authors compare the performance of different regression models for censored survival data in modeling the impact of prognostic factors on all-cause mortality in colon cancer. The data...

Go to Oxford Journals »  abstract

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

D. Y. Heng, M. J. MacKenzie, U. N. Vaishampayan, G. A. Bjarnason, J. J. Knox, M. H. Tan, L. Wood, Y. Wang, C. Kollmannsberger, S. North, F. Donskov, B. I. Rini and T. K. Choueiri.

in Annals of Oncology

June 2012; p ublished online November 2011 .

Journal Article. Subjects: Medical Oncology. 3167 words.

Background:

A subset of patients treated with initial anti-vascular endothelial growth factor (VEGF) therapy exhibit progressive disease (PD) as the best...

Go to Oxford Journals »  abstract

Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma

J. M. Pipas, B. I. Zaki, M. M. McGowan, M. J. Tsapakos, G. H. Ripple, A. A. Suriawinata, G. J. Tsongalis, T. A. Colacchio, S. R. Gordon, J. E. Sutton, A. Srivastava, K. D. Smith, T. B. Gardner, M. Korc, T. H. Davis, M. Preis, S. M. Tarczewski, T. A. MacKenzie and R. J. Barth.

in Annals of Oncology

November 2012; p ublished online May 2012 .

Journal Article. Subjects: Medical Oncology. 3812 words.

Background

Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of care...

Go to Oxford Journals »  abstract

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

J. P. Droz, X. Muracciole, N. Mottet, M. Ould Kaci, J. M. Vannetzel, N. Albin, S. Culine, J.-M. Rodier, J.-L. Misset, S. Mackenzie, E. Cvitkovic and G. Benoit.

in Annals of Oncology

August 2003; p ublished online August 2003 .

Journal Article. Subjects: Medical Oncology. 5727 words.

Background:

A randomized, multicenter phase II study evaluating oxaliplatin alone (OXA) and oxaliplatin–5-fluorouracil combination (OXFU) in advanced...

Go to Oxford Journals »  abstract

A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers

M. J. MacKenzie, H. W. Hirte, L. L. Siu, K. Gelmon, M. Ptaszynski, B. Fisher and E. Eisenhauer.

in Annals of Oncology

April 2004; p ublished online April 2004 .

Journal Article. Subjects: Medical Oncology. 4106 words.

Background:

OSI-211 (also known as NX211) is a liposomal preparation of the topoisomerase I inhibitor, lurtotecan, which has shown antitumor activity in phase I...

Go to Oxford Journals »  abstract

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

M. J. MacKenzie, B. I. Rini, P. Elson, A. Schwandt, L. Wood, M. Trinkhaus, G. Bjarnason and J. Knox.

in Annals of Oncology

January 2011; p ublished online July 2010 .

Journal Article. Subjects: Medical Oncology. 2109 words.

Background: Temsirolimus is an i.v. administered inhibitor of mammalian target of rapamycin with activity in the first-line setting in poor-prognosis patients with metastatic...

Go to Oxford Journals »  abstract

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

D. Y. C. Heng, T. K. Choueiri, B. I. Rini, J. Lee, T. Yuasa, S. K. Pal, S. Srinivas, G. A. Bjarnason, J. J. Knox, M. MacKenzie, U. N. Vaishampayan, M. H. Tan, S. Y. Rha, F. Donskov, N. Agarwal, C. Kollmannsberger, S. North and L. A. Wood.

in Annals of Oncology

January 2014; p ublished online January 2014 .

Journal Article. Subjects: Medical Oncology. 2850 words.

Background

Targeted therapies in metastatic renal cell carcinoma (mRCC) have been approved based on registration clinical trials that have strict eligibility...

Go to Oxford Journals »  abstract

P-300Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery

K. Spring, S. Lim, J. Descallar, W. Ng, W. Chua, P. de Souza, L. Bokey and S. MacKenzie.

in Annals of Oncology

June 2015; p ublished online June 2015 .

Journal Article. Subjects: Medical Oncology. 412 words.

Go to Oxford Journals »  abstract